Status:

RECRUITING

Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis

Lead Sponsor:

University Hospital, Toulouse

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

18-75 years

Brief Summary

This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily ove...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • French residents enrolled in the social security system
  • Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not
  • Patients scheduled for urodynamic assessment as part of their management
  • Exclusion criteria:
  • Pregnant or lactating females
  • Patients under legal guardianship
  • Untreated urinary tract infection at the time of inclusion
  • Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty

Exclusion

    Key Trial Info

    Start Date :

    December 4 2023

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2027

    Estimated Enrollment :

    400 Patients enrolled

    Trial Details

    Trial ID

    NCT06161376

    Start Date

    December 4 2023

    End Date

    December 1 2027

    Last Update

    December 31 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Toulouse Hospital

    Toulouse, France